Ironwood Pharmaceuticals (IRWD) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Silence Therapeutics Plc American Depository Share (SLN) over the past year, gaining 144.9% versus a gain of 81.3%. Over five years, SLN leads with a -56.4% price change compared with -71.7% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($639.5 million vs $591.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | SLN |
|---|---|---|
| Share price | $3.87 | $9.52 |
| Market cap | $639.48M | $591.71M |
| 1-day change | +3.20% | -3.05% |
| YTD return | +14.84% | +56.58% |
| 1-year return | +144.94% | +81.33% |
| 5-year return | -71.67% | -56.37% |
| P/E ratio (TTM) | 5.03 | — |
| Forward P/E | 2.58 | — |
| EPS (TTM) | $0.77 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.78 | $17.58 |
| 52-week low | $1.41 | $4.19 |
| Distance from 52-week high | -33.04% | -45.84% |
| Analyst consensus | none | buy |
| Avg. price target upside | +57.62% | +246.64% |
| Average volume | 2.02M | 1.12M |
| Shares outstanding | 165.24M | 62.15M |
| Employees | 100 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed SLN by 63.6 percentage points over the past year.
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
IRWD vs SLN FAQ
Which is bigger, Ironwood Pharmaceuticals or Silence Therapeutics Plc American Depository Share?
Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $639.48M compared with $591.71M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, IRWD or SLN?
IRWD returned +144.94% over the past 12 months, compared with +81.33% for SLN (price return, excluding dividends). Past performance does not predict future results.
Are Ironwood Pharmaceuticals and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.